NCT06054529Active, not recruiting
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
Source: ClinicalTrials.gov · Last updated 13 Mar 2025
Brief summary (registry, in English)
To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 2 (estimated)
- First submitted
- 20 Sept 2023
- Start date
- 11 Sept 2023
- Primary completion date
- 22 Jan 2024
- Lead sponsor
- AdventHealth Translational Research Institute
- Diseases
- Glioblastoma
- NCT number
- NCT06054529
What you commit to
- Study type: Observational
- Planned participants: 2
- From 11 Sept 2023 to the primary completion date, 22 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of Tru Niagen, Basis (or any other nicotinamide riboside (NR)-containing NAD+ booster) or niacin supplements within one month prior to Study Visit 1.
- Participation in studies involving investigational drug(s) within 30 days prior to Study Visit 1
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to Study Visit 1 (participants may not donate blood any time during the study, through the final study day)
Other illness
- Presence of any condition that, in the opinion of Dr. Field, compromises participant safety or data integrity or the participant's ability to complete study days.
Other
- Inability to obtain pre-operative IV access.
- Pregnancy, lactation or \< 9 months postpartum from the Study Visit 1 date.
Who the study is looking for
- Preoperative MRI consistent with a primary intracranial malignant brain tumor.
- Must be 18 years of age or older.
- Patient eligible for debulking surgery/resection.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AdventHealth Translational Research Institute Coordinator of this site? Confirm its status | Orlando | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.